150 related articles for article (PubMed ID: 15563240)
1. Palifermin: AMJ 9701, KGF-Amgen, recombinant human keratinocyte growth factor, rHu-KGF.
Drugs R D; 2004; 5(6):351-4. PubMed ID: 15563240
[TBL] [Abstract][Full Text] [Related]
2. Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair.
Finch PW; Rubin JS
Adv Cancer Res; 2004; 91():69-136. PubMed ID: 15327889
[TBL] [Abstract][Full Text] [Related]
3. Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support.
Radtke ML; Kolesar JM
J Oncol Pharm Pract; 2005 Sep; 11(3):121-5. PubMed ID: 16390600
[TBL] [Abstract][Full Text] [Related]
4. Keratinocyte growth factor in focus: A comprehensive review from structural and functional aspects to therapeutic applications of palifermin.
Sadeghi S; Kalhor H; Panahi M; Abolhasani H; Rahimi B; Kalhor R; Mehrabi A; Vahdatinia M; Rahimi H
Int J Biol Macromol; 2021 Nov; 191():1175-1190. PubMed ID: 34606789
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant.
Beaven AW; Shea TC
Drugs Today (Barc); 2007 Jul; 43(7):461-73. PubMed ID: 17728847
[TBL] [Abstract][Full Text] [Related]
6. Palifermin for oral mucositis after intensive therapy for hematologic cancers.
Spielberger R; Stiff P; Bensinger W; Gentile T; Weisdorf D; Kewalramani T; Shea T; Yanovich S; Hansen K; Noga S; McCarty J; LeMaistre CF; Sung EC; Blazar BR; Elhardt D; Chen MG; Emmanouilides C
N Engl J Med; 2004 Dec; 351(25):2590-8. PubMed ID: 15602019
[TBL] [Abstract][Full Text] [Related]
7. Palifermin and chemotherapy-induced oral mucositis.
Palmieri C; Vigushin D
N Engl J Med; 2005 Mar; 352(12):1264-5; author reply 1264-5. PubMed ID: 15791703
[No Abstract] [Full Text] [Related]
8. Clinical applications of palifermin: amelioration of oral mucositis and other potential indications.
Vadhan-Raj S; Goldberg JD; Perales MA; Berger DP; van den Brink MR
J Cell Mol Med; 2013 Nov; 17(11):1371-84. PubMed ID: 24251854
[TBL] [Abstract][Full Text] [Related]
9. Palifermin (Kepivance) for myelotoxic-therapy-related mucositis.
Med Lett Drugs Ther; 2005 Apr; 47(1207):36. PubMed ID: 15843784
[TBL] [Abstract][Full Text] [Related]
10. Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (palifermin): experimental studies in mice.
Dörr W; Bässler S; Reichel S; Spekl K
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):881-7. PubMed ID: 15936573
[TBL] [Abstract][Full Text] [Related]
11. Effects of palifermin on antitumor activity of chemotherapeutic and biological agents in human head and neck and colorectal carcinoma xenograft models.
Brake R; Starnes C; Lu J; Chen D; Yang S; Radinsky R; Borges L
Mol Cancer Res; 2008 Aug; 6(8):1337-46. PubMed ID: 18708365
[TBL] [Abstract][Full Text] [Related]
12. Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis.
McDonnell AM; Lenz KL
Ann Pharmacother; 2007 Jan; 41(1):86-94. PubMed ID: 17190850
[TBL] [Abstract][Full Text] [Related]
13. Palifermin: in myelotoxic therapy-induced oral mucositis.
Siddiqui MA; Wellington K
Drugs; 2005; 65(15):2139-46; discussion 2147-9. PubMed ID: 16225371
[TBL] [Abstract][Full Text] [Related]
14. Keratinocyte growth factor expression and activity in cancer: implications for use in patients with solid tumors.
Finch PW; Rubin JS
J Natl Cancer Inst; 2006 Jun; 98(12):812-24. PubMed ID: 16788155
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor.
Danilenko DM
Toxicol Pathol; 1999; 27(1):64-71. PubMed ID: 10367676
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant.
Meropol NJ; Somer RA; Gutheil J; Pelley RJ; Modiano MR; Rowinsky EK; Rothenberg ML; Redding SW; Serdar CM; Yao B; Heard R; Rosen LS
J Clin Oncol; 2003 Apr; 21(8):1452-8. PubMed ID: 12697866
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic evaluation of palifermin for mucosal protection from chemotherapy and radiation.
Weigelt C; Haas R; Kobbe G
Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):505-15. PubMed ID: 21417820
[TBL] [Abstract][Full Text] [Related]
18. Palifermin and chemotherapy-induced oral mucositis.
Awada A; Genot MT; Klastersky J
N Engl J Med; 2005 Mar; 352(12):1264-5; author reply 1264-5. PubMed ID: 15788506
[No Abstract] [Full Text] [Related]
19. Palifermin and chemotherapy-induced oral mucositis.
Köstler WJ; Hejna M; Zielinski CC
N Engl J Med; 2005 Mar; 352(12):1264-5; author reply 1264-5. PubMed ID: 15791702
[No Abstract] [Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic interactions between palifermin and heparin.
Yang BB; Gillespie B; Smith B; Smith W; Lissmats A; Rudebeck M; Kullenberg T; Olsson B
J Clin Pharmacol; 2015 Oct; 55(10):1109-18. PubMed ID: 25880826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
